A Year in Review and a Look to the Future: BTKi in CLL and MCL

In this episode, Ana Marin-Niebla, MD, PhD, and Stephan Stilgenbauer, MD, discuss key trial data on the use of BTK inhibitors in CLL and MCL throughout the past year, how these studies have impacted their practice, and what data they are looking forward to in the near future. The discussion includes analyses of: 

• SHINE: First-Line Ibrutinib + Bendamustine/Rituximab Followed by Rituximab Maintenance in Older Patients With MCL 
• TRIANGLE: Ibrutinib + Chemoimmunotherapy With or Without ASCT vs Chemoimmunotherapy Followed by ASCT in Younger Patients with Previously Untreated MCL 
• ZUMA-2: Brexucabtagene Autoleucel in R/R MCL 
• BRUIN: Pirtobrutinib for Previously Treated MCL 
• GLOW: Fixed-Duration Ibrutinib + Venetoclax vs Chlorambucil + Obinutuzumab in Previously Untreated CLL 
• FLAIR: Ibrutinib + Venetoclax vs FCR in Previously Untreated CLL 
• ELEVATE-RR: Acalabrutinib vs Ibrutinib in Previously Treated CLL 
• ALPINE: Zanubrutinib vs Ibrutinib in Previously Treated CLL 
• BRUIN: Pirtobrutinib for Previously Treated CLL

Presenters: 

Ana Marin-Niebla, MD, PhD
Hematology Consultant, Lymphoma Unit
Vall d’Hebron Institute of Oncology, Hematology Department
Hospital Universitario Vall d’Hebron
Barcelona, Spain

Stephan Stilgenbauer, MD
Medical Director Comprehensive Cancer Center Ulm
Head, Early Clinical Trials Unit
Head, Division of CLL Dept. of Internal Medicine III
University Medical Center
Ulm University
Ulm, Germany

Link to full program: 
https://bit.ly/3MNaUri

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.